Earlier charcoal haemoperfusion in fulminant hepatic failure.

Abstract

Charcoal haemoperfusion with a prostacyclin infusion for platelet protection was carried out daily in the treatment of 76 patients with fulminant hepatic failure. in the 31 patients who had been referred early and in whom the serial haemoperfusion was started while signs of grade III encephalopathy were still evident remarkable survival rates were obtained-70% for patients with paracetamol poisoning and 65% for the group overall. Cerebral oedema developed significantly less frequently in this group than in those patients in whom haemoperfusion was started later in the course of the disease, when signs of grade IV encephalopathy were already apparent (49% and 78% respectively, p less than 0.05), and this was likely to have been a major factor in their improved survival. Biocompatibility of the system was excellent, and both platelet and white-cell counts at the end of perfusion periods were the same as pre-perfusion values.

• Authors: A E Gimson, S Braude, P J Mellon, J Canalese, R Williams
• Journal: Lancet (London, England) (Lancet) Vol. 2 Issue 8300 Pg. 681-3 (Sep 25 1982) ISSN: 0140-6736 [Print] England
• PMID: 6126626 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Charcoal
• Epoprostenol

Topics

• Adult
• Brain Edema (prevention & control)
• Charcoal (therapeutic use)
• Clinical Trials as Topic
• Epoprostenol (pharmacology)
• Female
• Hemoperfusion (adverse effects, instrumentation, methods)
• Humans
• Liver Diseases (mortality, pathology, therapy)
• Male
• Platelet Adhesiveness (drug effects)
• Platelet Aggregation (drug effects)
• Time Factors